Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-057 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-057

Injection

Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
For retinal diseases including proliferative vitreoretinopathy (PVR), glaucoma, and diabetic retinopathy; conditions associated with inflammation, fibrosis, and pathological extracellular matrix remodeling. Clinical stage: Preclinical development. Anti-autotaxin RNA aptamer (chemically modified oligonucleotide therapeutic). Mechanism / Target: Selective inhibitor of autotaxin (ATX), an enzyme responsible for generating lysophosphatidic acid (LPA). Excessive ATX–LPA signaling contributes to fibrosis, inflammation, scarring, and pathological wound-healing responses in retinal disease. RBM-006 blocks ATX activity to reduce fibrotic proliferation and inflammation. Route / form: Intended for intravitreal administration (based on preclinical ophthalmic use). Differentiation: Targets ATX/LPA pathway — a mechanism not addressed by anti-VEGF agents. Offers potential benefit in diseases where fibrosis and scarring drive progression, such as PVR and diabetic retinopathy, and may complement or work independently of VEGF-targeted therapies.
Manufacturer #38604

A Japan-based biotech venture specializing in RNA aptamer drug discovery, with clinical-stage programs in ophthalmology and rare diseases. It leverages a proprietary aptamer-discovery platform and seeks global collaborations to bring next-generation nucleic-acid therapies to market.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.